Pharming Group N.V.
PHARHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframePharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe,. The $951.3M market capitalization puts PHAR squarely in small-cap range for its industry. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Market Cap
$951.3M
Beta
0.09
P/E (TTM)
67.35
P/E (Fwd)
205.65
EPS (TTM)
$0.20
EPS (Fwd)
$0.07
ROE
5.0%
ROA
4.9%
Cash
$170.2M
Total Debt
$116.2M
Free CF
$59.0M
52W Change
31.4%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $170.2M in cash comfortably exceeding the $116.2M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $59.0M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 5.0%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 4.9% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $205.6M (2022) to $376.1M (2025), reflecting a 83% increase over the period.
With a beta below 0.7, Pharming Group N.V. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing PHAR.